# Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Source: https://onco.cc/trials/nct05909436/  
OnCo record `nct05909436` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zimberelimab in advanced solid tumours, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.

## Summary

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors is a phase 1/2 interventional study registered as NCT05909436 by Guangzhou Gloria Biosciences Co., Ltd., with 107 participants planned, started 2022-10-31 and due to reach its primary completion in 2026-12. Interventions recorded: GLS-012 and GLS-010.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05909436
- Phase: 1/2
- Setting: A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)
- Sponsor: Guangzhou Gloria Biosciences Co., Ltd.
- Enrolled: 107

## Sources

- ClinicalTrials.gov NCT05909436: https://clinicaltrials.gov/study/NCT05909436

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Zimberelimab](https://onco.cc/drugs/zimberelimab/)

---
JSON: https://onco.cc/api/v1/entities/nct05909436.json